Part of UDG Healthcare, Sharp is a provider of clinical trial material supply chain services, manufacturing to clinical supplies packaging, labelling and distribution.
The project will develop the firm’s manufacturing and analytical capabilities, adding automated bottling, blistering and serialisation as well as IRT services for clinical trial management.
Sharp will also double its headcount, creating 73 new jobs and safeguarding a further 70 jobs with Welsh Government support.
The investment, which also includes £500,000 from the Welsh Government, will enable the company to satisfy increased demand for Phase III clinical and commercial services.
The initial phase will involve the acquisition and renovation of a 33,000sqm facility within the site.
The new unit will triple Sharp’s clinical service capacity for the global pharmaceutical, biotech and clinical research sectors.
Frank Lis, president of Sharp Clinical Services, said: “We are currently working at capacity at our site in Crickhowell, so this investment gives us a blank canvas to design a modern contract packaging, manufacturing and distribution facility that meets the evolving needs of drug development companies.
“The efficient nature of our extended operation will also allow us to seamlessly move clients’ late phase clinical projects to commercial scale within our wider global Sharp network of facilities. This really is a major milestone for our business in the UK and will ultimately deliver huge value to our clients in North America, Europe and Asia.”
Sharp plans to commence the first phase of the expansion project in 2017, with completion expected for late 2018.
Julie James, Wales’ skills and science minister, said: “This expansion by Sharp is welcome news for the sector, the local community and the wider Welsh economy and shows how Wales’ healthcare and biotech industries are going from strength to strength.”
Source: News – Packaging News | Jobs | Production | Design | Innovation